Author Correction: BRAF^V600E-mutant metastatic NSCLC: disease overview and treatment landscape

Affiliations

¹ Thoracic Cancer Group, Department of Medical Oncology, Gustave Roussy, Villejuif, France. david.planchard@gustaveroussy.fr.
² Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, USA.
³ Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁴ Department of Cancer Biology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁵ Department of Pulmonary Disease, Leiden University Medical Centre, Leiden, Netherlands.

Published Erratum

David Planchard et al. NPJ Precis Oncol. 2024.

. 2024 Jul 15;8(1):142.

doi: 10.1038/s41698-024-00633-7.

¹ Thoracic Cancer Group, Department of Medical Oncology, Gustave Roussy, Villejuif, France. david.planchard@gustaveroussy.fr.
² Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, USA.
³ Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁴ Department of Cancer Biology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁵ Department of Pulmonary Disease, Leiden University Medical Centre, Leiden, Netherlands.

No abstract available

Erratum for

BRAF^V600E-mutant metastatic NSCLC: disease overview and treatment landscape.
Planchard D, Sanborn RE, Negrao MV, Vaishnavi A, Smit EF. Planchard D, et al. NPJ Precis Oncol. 2024 Apr 16;8(1):90. doi: 10.1038/s41698-024-00552-7. NPJ Precis Oncol. 2024. PMID: 38627602 Free PMC article. Review.